Clinical trial
Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer
NCT00242190 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00242190 |
|---|---|
| Title | Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer |
| Official title | Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | Sanofi-Synthelabo Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Neoplasms |
| Intervention type | Drug, Procedure |
| Interventions | oxaliplatin, gemcitabine, radiation therapy |
| Enrollment | 40 |
| Start date | Jun 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Feb 1, 2010 |
| First posted | Oct 19, 2005 |
| Last update posted | Nov 15, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: